A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Saved in:
| Title: | A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma. |
|---|---|
| Authors: | Sun W; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA., Veeramachaneni N; Cardiothoracic Surgery Division, Department of Surgery, Saint Louis University School of Medicine, Saint Louis, Missouri, USA., Al-Rajabi R; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA., Madan R; Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA., Kasi A; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA., Al-Kasspooles M; University of Kansas Cancer Center, Kansas City, Kansas, USA.; Division of Surgical Oncology, Department of Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA., Baranda J; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA., Saeed A; Hematology-Oncology Division, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Phadnis MA; Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA., Godwin AK; University of Kansas Cancer Center, Kansas City, Kansas, USA.; Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA., Olyaee M; Division of Gastroenterology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., Streeter N; University of Kansas Cancer Center, Kansas City, Kansas, USA., Nagji A; University of Kansas Cancer Center, Kansas City, Kansas, USA.; Department of Cardiothoracic Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA., Dai J; Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA., Williamson S; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.; University of Kansas Cancer Center, Kansas City, Kansas, USA. |
| Source: | Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 16098-16107. Date of Electronic Publication: 2023 Jun 16. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2045-7634 |
|---|---|
| DOI: | 10.1002/cam4.6263 |
